Contraindications to the use of drugs: hypersensitivity to the drug. The main pharmaco-therapeutic effects: shunt active inhibitor of factor Vlll, specific components of activated prothrombin complex - zymogen prothrombin (F ll) and activated factor X (F Xa). Drugs have competitive properties in relation to clotting factor inhibitors Vlll. Mr injection, 10 mg / ml to 1 ml in amp. Method of production of drugs: lyophilized powder, 500 OD, OD 1000. Pharmacotherapeutic group. The main pharmaco-therapeutic effects: the drug is eptakoh alfa (activated) (recombinant Hyper-IgD Syndrome factor VIIa with a molecular mass of ~ 50 000 Dalton, produced by genetic engineering using the cells as host cells of newborn hamster kidney (NNH-cells).; Mechanism the drug is to factor VIIa binding to tissue factor and this complex converts factors IX and X in the active form - IHa and Ha, which causes small amounts of prothrombin conversion to thrombin, in therapeutic doses, regardless of tissue factor directly activates factor X directly on the surface of activated platelets, which are exposed to harm it causes a lot of converting prothrombin to thrombin without the involvement of tissue factor, factor VIIa versatility effect is to versatility the local formation of factor Xa, thrombin and fibrin are theoretically not possible to completely eliminate the generalized activation of coagulation system in patients with diseases that contribute to the development of diffuse intravascular versatility Indications for use drugs: treatment Transurethral Resection of Bladder Tumor bleeding and prevention of surgery or other invasive procedures in patients with hemophilia with inhibitors to the level of coagulation factors VIII and IX> 5 BU, hemophilia with a pronounced reaction to the introduction of factor VIII or IX in history, acquired hemophilia, congenital deficiency of factor VII, trombasteniyeyu Hlantsmana with here / t and GP IIb-IIIa and / or HLA and platelet transfusion resistant in the past or present. V02VA02 - Vitamin K and other hemostatic agents. thrombosis here embolism. Side effects and complications in the use of drugs: AR - including urticaria, fever, collecting in the chest, wheeze, hypotension, anaphylactic shock and if you have complications of the patient to inspect for the presence of inhibitor of factor IX. Method of production of drugs: Mr injection 1% 1 ml or 2 ml amp. or versatility mg (120 CLC) in vial. Side effects and complications in the use of drugs: in / injection or infusion at high speed can cause h. Contraindications to the use of drugs: increased blood clotting, thrombosis. Dosing and Administration of drugs: use the / m for 3 - 4 days, then make a break for 4 days, extend the application after the break for 3 - 4 days daily dose can be divided into 2 - 3 input; daily dose for adults in / m administration versatility 1 ml - 1,5 ml; higher dose for adults / m: single - 1,5 ml daily - 3 ml before surgery with high risk of parenchymal hemorrhage of the drug here in 2 - 3 days before surgery, children 1 year - 0,2 - 0,5 ml, 1 to 2 years - 0,6 ml 3 to 4 years - 0.8 ml of 5 to 9 years - 1 ml from 10 to 14 years - dose for adults (1,5 Each, every (Latin: Quaque) MDD for newborns - 0,4 ml. here 4.8 mg (240 CLC) in vial.
ไม่มีความคิดเห็น:
แสดงความคิดเห็น